Belizatinib

Drug Profile

Belizatinib

Alternative Names: TSR-011

Latest Information Update: 31 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen
  • Developer TESARO
  • Class Antineoplastics; Benzamides; Benzimidazoles; Piperidines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 31 Jul 2017 Chemical structure information added
  • 14 Jul 2015 TSR 011 is still in phase I/II trials for Solid tumours, Non-small cell lung cancer and Lymphoma in USA and United Kingdom
  • 14 Jul 2015 Phase-I/II clinical trials in Solid tumours, Non-small cell lung cancer and Lymphoma in Poland, Spain, Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top